132 related articles for article (PubMed ID: 3914816)
21. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
22. Beta-cell function and diabetic control in insulin dependent diabetes melletus.
Faber OK
Acta Endocrinol Suppl (Copenh); 1985; 272():73-7. PubMed ID: 3914807
[TBL] [Abstract][Full Text] [Related]
23. Insulin and C-peptide levels after oral and intravenous glucose. Contribution of enteroinsular axis to insulin secretion.
Hampton SM; Morgan LM; Tredger JA; Cramb R; Marks V
Diabetes; 1986 May; 35(5):612-6. PubMed ID: 3514335
[TBL] [Abstract][Full Text] [Related]
24. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus.
Elahi D; Andersen DK; Muller DC; Tobin JD; Brown JC; Andres R
Diabetes; 1984 Oct; 33(10):950-7. PubMed ID: 6383904
[TBL] [Abstract][Full Text] [Related]
25. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients.
Rudovich NN; Rochlitz HJ; Pfeiffer AF
Diabetes; 2004 Sep; 53(9):2359-65. PubMed ID: 15331546
[TBL] [Abstract][Full Text] [Related]
26. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans.
Hartter E; Svoboda T; Ludvik B; Schuller M; Lell B; Kuenburg E; Brunnbauer M; Woloszczuk W; Prager R
Diabetologia; 1991 Jan; 34(1):52-4. PubMed ID: 2055340
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.
Meier JJ; Gallwitz B; Kask B; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetes; 2004 Dec; 53 Suppl 3():S220-4. PubMed ID: 15561915
[TBL] [Abstract][Full Text] [Related]
28. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
29. Gastric inhibitory polypeptide in newly diagnosed ketotic type I (insulin-dependent) diabetics.
Krarup T; Madsbad S; Moody AJ
Acta Med Scand; 1988; 223(5):437-41. PubMed ID: 3287838
[TBL] [Abstract][Full Text] [Related]
30. [The role of incretins. Type 2 diabetes with new beginnings].
MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
[No Abstract] [Full Text] [Related]
31. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus.
Hanabusa T; Kubo K; Oki C; Nakano Y; Okai K; Sanke T; Nanjo K
Diabetes Res Clin Pract; 1992 Jan; 15(1):89-96. PubMed ID: 1541240
[TBL] [Abstract][Full Text] [Related]
32. Hormonal enteroinsular axis in newborn infants of insulin-treated diabetic mothers.
Knip M; Kääpä P; Koivisto M
J Clin Endocrinol Metab; 1993 Nov; 77(5):1340-4. PubMed ID: 8077330
[TBL] [Abstract][Full Text] [Related]
33. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
34. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
[TBL] [Abstract][Full Text] [Related]
35. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.
O'Harte FP; Mooney MH; Kelly CM; Flatt PR
J Endocrinol; 2000 Jun; 165(3):639-48. PubMed ID: 10828847
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes.
Miki H; Matsuyama T; Fujii S; Komatsu R; Nishioeda Y; Omae T
Diabetes Res Clin Pract; 1992 Nov; 18(2):99-105. PubMed ID: 1478158
[TBL] [Abstract][Full Text] [Related]
37. Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity.
Heptulla RA; Tamborlane WV; Cavaghan M; Bronson M; Limb C; Ma YZ; Sherwin RS; Caprio S
Pediatr Res; 2000 May; 47(5):628-33. PubMed ID: 10813588
[TBL] [Abstract][Full Text] [Related]
38. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
39. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
40. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
